ImmunityBio enters collaboration with BeiGene on Anktiva trial

ImmunityBio (IBRX) announced it has entered into a collaboration and supply agreement with BeiGene (BGNE) to conduct a confirmatory randomized Phase 3 clinical trial, combining BeiGene’s tislelizumab, a PD-1 checkpoint inhibitor, and ImmunityBio’s Anktiva. The Phase 3 ResQ201A-NSCLC study aims to confirm the efficacy and safety of combination Anktiva plus CPI therapy previously demonstrated in the trial QUILT 3.055 and provide evidence of the potential for these two immunotherapeutic agents to improve overall survival in patients with advanced or metastatic NSCLC who have acquired resistance to immune CPI therapy. ImmunityBio will conduct this confirmatory Phase 3 trial globally across multiple sites; when fully enrolled, it is expected to include 462 participants.